NCT Number: NCT04965870
Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Observational
General Hospital "Venizeleio - Pananio", Heraklion, Crete, Greece
The aim of this analysis is to record clinical practice and to collect real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population. Main objectives include to assess physician's choice of treatment in chemoresistant metastatic colorectal cancer with FTD/TPI in third line and beyond In addition, the clinicopathologic features related to metastatic colorectal cancer (focus on molecular profile), duration of treatment, dose modification and toxicity will be analyzed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No exclusion criteria have been established for this observational and retrospective study.
Trifluridine/ Tipiracil is an oral combination of an antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase (TPase) inhibitor, tipiracil hydrochloride.
Other names: FTD/TPI, TAS 102
Time frame: Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.
PFS is defined as the time interval from initiation of treatment to the first date of documented tumor progression or death from any cause, whichever occurs first.
Time frame: Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.
Overall survival is defined as the time interval from initiation of treatment to the date of death due to any cause.
Time frame: Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.
PFS rate at 6 and 8 months corresponding to the percentage of patients surviving without any documented progression of the disease at 6 and 8 months after treatment initiation.
Time frame: Retrospective data analysis from January 2018 to at least 3 months prior to being included in the study.
The DCR is defined as the proportion of patients with objective evidence of complete response (CR), the proportion of patients with objective evidence of partial response (PR), and the proportion of patients with objective evidence of stable disease (SD).
Hellenic Study Group of Psychoneuroimmunology in Cancer
Network
A Retrospective Observational Study of Trifluridine/ Tipiracil (TAS-102) in Chemorefractory Metastatic Colorectal Cancer (mCRC) in Greece. Real World Data on Clinical Benefit.
Acronym: RETRO-TAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05513742
Colon Cancer, Colonic Diseases
Hot Springs, Arkansas, United States
View Trial DetailsNCT02821559
Colonic Diseases, Colorectal Neoplasms
Besançon, France
View Trial DetailsNCT05128032
Adenocarcinoma, Carcinoma
Boston, Massachusetts, United States
View Trial DetailsNCT05840263
Colonic Diseases, Colorectal Neoplasms
Aurora, Colorado, United States
View Trial Details